前臨床イメージング市場：製品、用途、エンドユーザー別-2025-2030年の世界予測

前臨床イメージング市場は、2023年に24億8,000万米ドルと評価され、2024年には26億米ドルに達すると予測され、CAGR 4.91％で成長し、2030年には34億8,000万米ドルになると予測されています。

前臨床イメージングは、医薬品開発プロセスに不可欠な要素であり、疾患モデルの研究、医薬品候補の有効性の評価、生体内の生物学的プロセスの理解によく使用されます。その範囲は、MRI、PET、CT、光学、超音波などの様々な画像モダリティを含み、トランスレーショナルリサーチに不可欠な詳細な空間的・時間的データを提供します。前臨床イメージングの必要性は、動物モデルを研究するためのハイスループットで定量可能な非侵襲的ツールを提供することにより、創薬プロセスを加速する能力にあります。主に腫瘍学、神経学、心臓病学、感染症学に応用されています。

前臨床イメージングの市場開拓は、主にイメージング技術の進歩、研究開発投資の増加、効果的な医薬品開発を必要とする慢性疾患の有病率の上昇の影響を受けています。分子イメージングや、画像分析と解釈を強化するためのAIと機械学習の統合に新たな機会が存在します。市場関係者への提言としては、学術研究機関との共同プロジェクトに注力し、画像解析におけるサービス提供を拡大することが挙げられます。しかし、機器やメンテナンスの高コスト、規制上のハードル、動物実験をめぐる倫理的配慮などの課題は依然として残っており、市場成長の妨げになる可能性があります。

技術革新という点では、費用対効果の高い画像技術の開発と画像解像度の向上が主要な研究分野です。さらに、イメージングシステムの小型化やマルチモーダルイメージングソリューションの採用にも可能性があります。また、前臨床イメージングがバイオマーカーの同定や治療法のカスタマイズに大きく貢献できる個別化医療にもビジネスチャンスがあります。前臨床イメージング市場はダイナミックで競争的な性質を示し、技術的進歩が差別化の重要な原動力となっています。利害関係者は、持続的な成長のために新たな動向を効果的に活用するために、最新の技術革新や規制状況を常に把握しておく必要があります。

市場力学：急速に進化する前臨床イメージング市場の主要市場インサイトを公開

前臨床イメージング市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 製薬企業による研究開発活動の活発化
  • 生物医学研究拡大のための政府投資と資金提供の増加
  • 臨床研究機関（CRO）の増加
• 市場抑制要因
  • 画像診断機器および前臨床イメージングのメンテナンス費用の高騰
• 市場機会
  • 画像解析を向上させるための前臨床イメージングへの先端技術の搭載の増加
  • 個別化医療の開発への注目の高まり
• 市場の課題
  • 動物実験に関連する厳しい規制と倫理的懸念

ポーターのファイブフォース：前臨床イメージング市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：前臨床イメージング市場における外部からの影響の把握

外部マクロ環境要因は、前臨床イメージング市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析前臨床イメージング市場における競合情勢の把握

前臨床イメージング市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス前臨床イメージング市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、前臨床イメージング市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨前臨床イメージング市場における成功への道筋を描く

前臨床イメージング市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬会社の研究開発活動の増加
    • バイオメディカル調査の拡大に向けた政府の投資と資金の増加
    • 臨床調査機関（CRO）の増加
  • 抑制要因
    • 画像機器とメンテナンスのコストが高い
  • 機会
    • 画像解析を向上させるために前臨床イメージングに先進技術を取り入れる
    • 個別化医療の開発への注目が高まる
  • 課題
    • 動物調査に伴う厳しい規制と倫理的懸念
• 市場セグメンテーション分析
  • 製品：特定の調査ニーズに合わせた前臨床研究におけるモダリティの使用の増加
  • エンドユーザー：製薬会社やバイオ医薬品会社による新薬開発のための前臨床イメージングの採用増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 前臨床イメージング市場：製品別

• モダリティ
  • 磁性粒子イメージング
  • 磁気共鳴画像
  • マイクロコンピュータ断層撮影
  • 光学イメージング
  • 陽電子放出断層撮影
  • 単一光子放出コンピュータ断層撮影
• 試薬
  • 生物発光イメージング試薬
  • 蛍光イメージング試薬
  • MRI造影剤
  • PET放射性トレーサー
  • 超音波造影剤
  • X線CT造影剤

第7章 前臨床イメージング市場：用途別

• 創薬
• 研究開発

第8章 前臨床イメージング市場：エンドユーザー別

• 学術機関および政府調査機関
• 契約調査機関（CRO）
• 製薬・バイオテクノロジー企業

第9章 南北アメリカの前臨床イメージング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の前臨床イメージング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの前臨床イメージング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Revvity, Inc.の革新的な前臨床イメージングソリューションがWMICで発表されました2023
• 戦略分析と提言

企業一覧

• Advanced Molecular Vision, Inc.
• Angstrom Advanced Inc.
• Aspect Imaging Ltd.
• Berthold Technologies
• Bruker Corporation
• Euro-BioImaging ERIC
• FUJIFILM Holdings America Corporation
• IVIM Technology Corp.
• KUBTEC Technology
• LI-COR, Inc.
• Mediso Ltd.
• Milabs BV
• Miltenyi Biotec GmbH
• MR Solutions Group
• Peira bvba
• PerkinElmer Inc.
• Revvity, Inc.
• Scitech Pty Ltd.
• United Imaging Healthcare Co., Ltd.

LIST OF FIGURES

• FIGURE 1. PRECLINICAL IMAGING MARKET RESEARCH PROCESS
• FIGURE 2. PRECLINICAL IMAGING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PRECLINICAL IMAGING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. PRECLINICAL IMAGING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. PRECLINICAL IMAGING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PRECLINICAL IMAGING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PRECLINICAL IMAGING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PRECLINICAL IMAGING MARKET DYNAMICS
• TABLE 7. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. CANADA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. CANADA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 49. CANADA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 50. CANADA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. CHINA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. CHINA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 76. CHINA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 77. CHINA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. CHINA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. INDIA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. INDIA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 81. INDIA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 82. INDIA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. INDIA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. ITALY PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 166. ITALY PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 167. ITALY PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 168. ITALY PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. ITALY PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. POLAND PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 186. POLAND PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 187. POLAND PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 188. POLAND PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. POLAND PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. QATAR PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. QATAR PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 192. QATAR PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 193. QATAR PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. QATAR PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM PRECLINICAL IMAGING MARKET SIZE, BY MODALITIES, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM PRECLINICAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM PRECLINICAL IMAGING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 240. PRECLINICAL IMAGING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 241. PRECLINICAL IMAGING MARKET, FPNV POSITIONING MATRIX, 2023

The Preclinical Imaging Market was valued at USD 2.48 billion in 2023, expected to reach USD 2.60 billion in 2024, and is projected to grow at a CAGR of 4.91%, to USD 3.48 billion by 2030.

Preclinical imaging is an essential component of the drug development process, often used to study disease models, evaluate drug candidate efficacy, and understand biological processes in vivo. Its scope includes various imaging modalities such as MRI, PET, CT, optical, and ultrasound, providing detailed spatial and temporal data crucial for translational research. The necessity of preclinical imaging lies in its ability to accelerate the drug discovery process by offering high-throughput, quantifiable, non-invasive tools for studying animal models. It is applied across pharmaceutical, biotechnology, and research institutions, primarily serving applications in oncology, neurology, cardiology, and infectious diseases.

The market growth of preclinical imaging is primarily influenced by advancements in imaging technology, increased investment in R&D, and the rising prevalence of chronic diseases necessitating effective drug development. Emerging opportunities exist in molecular imaging and the integration of AI and machine learning to enhance image analysis and interpretation. Recommendations for market players include focusing on collaborative projects with academic and research institutions and expanding service offerings in image analysis. However, challenges persist, including high costs of equipment and maintenance, regulatory hurdles, and the ethical considerations surrounding animal testing, which could potentially hinder market growth.

In terms of innovation, developing cost-effective imaging technologies and enhancing imaging resolution are prime areas of research. Additionally, there is potential in the miniaturization of imaging systems and the adoption of multi-modal imaging solutions. Businesses can also explore opportunities in personalized medicine, wherein preclinical imaging can significantly contribute to identifying biomarkers and tailoring treatments. The preclinical imaging market exhibits a dynamic and competitive nature, with technological advancements being a key driver for differentiation. Stakeholders must stay abreast of the latest innovations and regulatory landscapes to effectively leverage emerging trends for sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preclinical Imaging Market

The Preclinical Imaging Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing research & development activities by pharmaceutical companies
  • Growing government investment and funding for expanding biomedical research
  • Rising number of clinical research organizations (CROs)
• Market Restraints
  • High cost of imaging equipment and maintenance of preclinical imaging
• Market Opportunities
  • Increasing incorporation of advanced technologies in preclinical imaging to improve image analysis
  • Rising focus on the development of personalized medicines
• Market Challenges
  • Strict regulations and ethical concerns associated with animal research

Porter's Five Forces: A Strategic Tool for Navigating the Preclinical Imaging Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preclinical Imaging Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Preclinical Imaging Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preclinical Imaging Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Preclinical Imaging Market

A detailed market share analysis in the Preclinical Imaging Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preclinical Imaging Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preclinical Imaging Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Preclinical Imaging Market

A strategic analysis of the Preclinical Imaging Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Preclinical Imaging Market, highlighting leading vendors and their innovative profiles. These include Advanced Molecular Vision, Inc., Angstrom Advanced Inc., Aspect Imaging Ltd., Berthold Technologies, Bruker Corporation, Euro-BioImaging ERIC, FUJIFILM Holdings America Corporation, IVIM Technology Corp., KUBTEC Technology, LI-COR, Inc., Mediso Ltd., Milabs BV, Miltenyi Biotec GmbH, MR Solutions Group, Peira bvba, PerkinElmer Inc., Revvity, Inc., Scitech Pty Ltd., and United Imaging Healthcare Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Preclinical Imaging Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Modalities and Reagents. The Modalities is further studied across Magnetic Particle Imaging, Magnetic Resonance Imaging, Micro-Computed Tomography, Optical Imaging, Positron Emission Tomography, and Single-Photon Emission Computed Tomography. The Reagents is further studied across Bioluminescent Imaging Reagents, Fluorescent Imaging Reagents, MRI Contrasting Reagents, PET Radioactive Tracers, Ultrasound Contrasting Reagents, and X-ray CT Contrasting Reagents.
• Based on Application, market is studied across Drug Discovery and Research & Development.
• Based on End-User, market is studied across Academic & Government Research Institutes, Contract Research Organizations (CROs), and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing research & development activities by pharmaceutical companies
    • 5.1.1.2. Growing government investment and funding for expanding biomedical research
    • 5.1.1.3. Rising number of clinical research organizations (CROs)
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of imaging equipment and maintenance of preclinical imaging
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing incorporation of advanced technologies in preclinical imaging to improve image analysis
    • 5.1.3.2. Rising focus on the development of personalized medicines
  • 5.1.4. Challenges
    • 5.1.4.1. Strict regulations and ethical concerns associated with animal research
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Growing usage of modalities in preclinical studies for specific research needs
  • 5.2.2. End-User: Increasing adoption of preclinical imaging by pharmaceutical & biopharmaceutical companies to develop new drugs
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Preclinical Imaging Market, by Product

• 6.1. Introduction
• 6.2. Modalities
  • 6.2.1. Magnetic Particle Imaging
  • 6.2.2. Magnetic Resonance Imaging
  • 6.2.3. Micro-Computed Tomography
  • 6.2.4. Optical Imaging
  • 6.2.5. Positron Emission Tomography
  • 6.2.6. Single-Photon Emission Computed Tomography
• 6.3. Reagents
  • 6.3.1. Bioluminescent Imaging Reagents
  • 6.3.2. Fluorescent Imaging Reagents
  • 6.3.3. MRI Contrasting Reagents
  • 6.3.4. PET Radioactive Tracers
  • 6.3.5. Ultrasound Contrasting Reagents
  • 6.3.6. X-ray CT Contrasting Reagents

7. Preclinical Imaging Market, by Application

• 7.1. Introduction
• 7.2. Drug Discovery
• 7.3. Research & Development

8. Preclinical Imaging Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Government Research Institutes
• 8.3. Contract Research Organizations (CROs)
• 8.4. Pharmaceutical & Biotechnology Companies

9. Americas Preclinical Imaging Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Preclinical Imaging Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Preclinical Imaging Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Revvity, Inc.'s Innovative Preclinical Imaging Solutions Unveiled at WMIC 2023
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Advanced Molecular Vision, Inc.
• 2. Angstrom Advanced Inc.
• 3. Aspect Imaging Ltd.
• 4. Berthold Technologies
• 5. Bruker Corporation
• 6. Euro-BioImaging ERIC
• 7. FUJIFILM Holdings America Corporation
• 8. IVIM Technology Corp.
• 9. KUBTEC Technology
• 10. LI-COR, Inc.
• 11. Mediso Ltd.
• 12. Milabs BV
• 13. Miltenyi Biotec GmbH
• 14. MR Solutions Group
• 15. Peira bvba
• 16. PerkinElmer Inc.
• 17. Revvity, Inc.
• 18. Scitech Pty Ltd.
• 19. United Imaging Healthcare Co., Ltd.